10x Genomics Inc. (TXG) experienced a significant after-hours plunge, with its stock dropping 10.85% following the release of its fourth-quarter and full-year 2025 financial results.
The company reported Q4 earnings per share of $(0.13), beating analyst estimates, and revenue of $166.03 million, also surpassing expectations. However, investors reacted negatively to the company's 2026 revenue guidance, which projects revenue between $600 million and $625 million, implying only modest growth compared to 2025's total revenue of $642.82 million.
Analyst sentiment also contributed to the sell-off, with the median 12-month price target of $18.00 sitting below the stock's previous closing price, indicating limited upside potential according to Wall Street expectations.